Effect of the histone deacetylase inhibitor depsipeptide on B-cell differentiation in both TEL-AML1-positive and negative childhood acute lymphoblastic leukemia

The fusion protein TEL-AML1 in t(12;21)+ acute lymphoblastic leukemia (ALL) recruits co-repressors and histone deacetylases (HDAC), which transrepress AML1 target genes. Normal bone marrow cells were more resistant to HDAC inhibitor FK228 induced cell killing than were cells from ALL patients with or without t(12;21). FK228 induced differentiation in ALL, irrespective of the presence of t(12;21).
FK228 (FR901228, depsipeptide) have been shown to induce cell differentiation in myeloid leukemias, to inhibit cell proliferation and to enhance apoptosis in several types of cancer cells.  

We studied the cytotoxic effect of HDAC inhibition alone and in combination with L-asparaginase in TEL-AML1-negative and positive leukemic cells of children with ALL at initial diagnosis to gain more insight into the potential use of HDAC inhibitors in the treatment of TEL-AML1-positive ALL. In addition, the effect of HDAC inhibition on differentiation of these B-lineage leukemic cells was studied.  

Leukemic cells of 29 children with common/pre B-ALL at initial diagnosis were collected at the Erasmus MC - Sophia Children’s Hospital, the Dutch Childhood Oncology Group (DCOG) and the German COALL study group. Bone marrow samples from four healthy children were included as controls. The in vitro cytotoxicity of the HDAC inhibitors FK228 and sodium butyrate as well as L-asparaginase was determined using the MTT assay as described previously.  

Despite the presence of more binding sites for HDAC inhibitors on the TEL-AML1 fusion gene compared to wild type TEL or AML1 genes, the cytotoxicity of the HDAC inhibitor FK228 did not differ between TEL-AML1 positive (median LC50 value 1.0 ng/mL, P25-P75: 0.8-1.3) and TEL-AML1-negative ALL cells (median LC50 value 0.8 ng/mL, P25-P75: 0.6-1.2; p=0.3) (Figure 1). Normal bone marrow samples were a median of 2-fold more resistant than were ALL cases (median LC50 value 2.0 ng/mL, P25-P75: 1.1-2.6 and median LC50 value 1.0 ng/mL, P25-P75: 0.7-1.2 respectively; p=0.03). Similar results were obtained with sodium butyrate, another HDAC inhibitor.  

TEL-AML1-positive ALL patients are known to be more sensitive to L-asparaginase than are TEL-AML1-negative ALL patients, and the mechanism of action of L-asparaginase is different from these genetic subtypes. We observed that FK228 sensitized both TEL-AML1-positive and negative ALL cases to the cytotoxic effect of L-asparaginase. However, this sensitizing effect was not caused by a synergism between FK228 and L-asparaginase, but could be explained by an additive effect caused by the cytotoxicity of FK228 itself.  

Since FK228 was shown to induce myeloid differentiation, we studied the B-cell differentiation effect of FK228 in samples from five TEL-AML1-positive and five TEL-AML1-negative ALL patients (matched for age 1-10 years, common/preB immunophenotype, no hyperdiploidy (>50 chromosomes), absence of AML, rearrangement and t(9;22) [BCR-ABL]). After 4 days of exposure to FK228 or control medium, the expression of B-cell differentiation markers was measured by flow cytometry. Three selected quadruple immunostainings were used to analyze FK228-induced changes in the differentiation stage of precursor B-cells as described previously. Incubation with 0.1 or 0.4 ng/mL FK228 had no differentiation effect compared to exposure to culture medium only. However, exposure to 1.1 ng/mL FK228 resulted in a clear and significant effect on the expression of CD10, CD19, and TdT (Table 1). The decreases in CD19, TdT, and CD10 as well as the slight increases in CD20, CD22 and CD45 expression corresponded to the induction of differentiation towards a more mature B-cell stage. This effect of 1.1 ng/mL FK228 was not, however, different between TEL-AML1-positive and negative ALL cases. This suggests that the effect of HDAC inhibitors is independent of the genetic subtype. Studies in acute myeloid leukemia also found that HDAC inhibition restores the differentiation process independently of the genetic subtype.  

### Table 1. FK228-induced B-cell differentiation in childhood ALL.

<table>
<thead>
<tr>
<th>Marker</th>
<th>Fluorescence Index* unexposed median (P25-P75)</th>
<th>Fluorescence Index* exposed to 1.1 ng/mL FK228 median (P25-P75)</th>
<th>fold change</th>
<th>paired t-test p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD10</td>
<td>751.1 (558.3-964.4)</td>
<td>550.3 (305.2-834.1)</td>
<td>1.4</td>
<td>0.007</td>
</tr>
<tr>
<td>CD19</td>
<td>208.8 (136.7-358.1)</td>
<td>131.8 (76.1-242.2)</td>
<td>1.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CD20</td>
<td>10.1 (3.8-24.2)</td>
<td>18.6 (5.4-24.2)</td>
<td>1.8</td>
<td>0.15</td>
</tr>
<tr>
<td>CD22</td>
<td>112.6 (100.3-316.1)</td>
<td>122.4 (83.3-273.2)</td>
<td>1.1</td>
<td>0.82</td>
</tr>
<tr>
<td>CD34</td>
<td>32.2 (8.6-85.1)</td>
<td>31.0 (13.3-70.5)</td>
<td>1.0</td>
<td>0.10</td>
</tr>
<tr>
<td>CD45</td>
<td>93.3 (42.7-111.2)</td>
<td>104.6 (64.9-130.9)</td>
<td>1.1</td>
<td>0.09</td>
</tr>
<tr>
<td>TdT</td>
<td>50.8 (26.1-67.4)</td>
<td>19.4 (12.2-31.2)</td>
<td>2.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CyIgM</td>
<td>24.8 (14.7-56.7)</td>
<td>26.3 (15.4-36.7)</td>
<td>1.1</td>
<td>0.15</td>
</tr>
<tr>
<td>SmIgM</td>
<td>10.6 (8.0-13.1)</td>
<td>9.0 (7.7-11.1)</td>
<td>1.2</td>
<td>0.16</td>
</tr>
</tbody>
</table>

* The fluorescence index (FI) is the mean fluorescence intensity of the specific antibody by its isotypic control antibody. ** The fold-change value for each differentiation marker represents the ratio between the FI of FK228 exposed cells compared to the FI of culture medium (control)-treated cells. Statistically significant p-values are underlined.
Although our results showed that FK228 induced differentiation of malignant B-cells, the effect of this HDAC inhibitor was not selective for TEL-AML-positive ALL patients. However, the 2-fold difference in toxicity of FK228 between ALL and normal bone marrow samples may be indicative of a therapeutic advantage from using FK228 in the treatment of ALL. The additive effect of FK228 on L-asparaginase cytotoxicity as well as the induction of B-cell differentiation encourages further studies on the efficacy of HDAC inhibitors in the treatment of precursor B-ALL, irrespective of TEL-AML1 status.

Wendy A.G. Stams,* Monique L. den Boer,* H. Berna Beverloo,* Karin M. Kazemier,* Elisabeth R. van Wering,* Gitta E. Janka-Schaub,† Rob Pieters*  
*Erasmus MC, Sophia Children’s Hospital, University Medical Center Rotterdam, Division of Pediatric Oncology/Hematology, Rotterdam, The Netherlands; †Erasmus MC, University Medical Center Rotterdam, Department of Clinical Genetics, Rotterdam, The Netherlands; #Dutch Childhood Oncology Group, The Hague, The Netherlands; @COALL study group, University Children’s Hospital Hamburg, Germany

Funding: this study was financially supported by a grant from the Sophia Foundation for Medical Research (SSWO grant 309) and the Pediatric Oncology Foundation, Rotterdam, The Netherlands.  
Acknowledgments: we wish to express our gratitude to the members of the DCOG and the German COALL study group for their support of this study by providing leukemic samples and to Fujisawa Pharmaceutical Co., Osaka, Japan for providing the HDAC inhibitor, FK228.

Key words: histone deacetylase inhibitor, FK228, FR901228, depsipeptide, acute lymphoblastic leukemia, TEL-AML1.

Correspondence: Monique L. den Boer, Erasmus MC, Sophia Children’s Hospital, Division of Pediatric Oncology / Hematology, Dr. Molewaterplein 60, 3015 CJ Rotterdam, The Netherlands. Phone: international +31.10.4089379. Fax: international +31.10.4089433. E-mail: m.l.denboer@erasmusmc.nl

References